NewKerala.com

Australia Defies US Pressure, Refuses to Negotiate Drug Subsidy Scheme

The Australian government has firmly stated it will not negotiate the core principles of its Pharmaceutical Benefits Scheme with the United States. This declaration comes after US President Donald Trump signed an executive order imposing a 100% tariff on imports of certain patented pharmaceuticals. The US administration has criticized the Australian scheme, claiming it undervalues American innovation through its drug pricing practices. Australian officials express disappointment over the tariffs but remain confident that major domestic firms with US manufacturing may be exempt.

Key Points: Australia Stands Firm on Drug Subsidies Amid US Tariff Pressure

  • Australia refuses to alter drug subsidy scheme
  • US imposes 100% tariff on some pharma imports
  • US claims Australian pricing undervalues innovation
  • Scheme prevents commercial bidding wars for drugs
2 min read

Australian govt rules out negotiating with US on pharmaceutical tariffs

Australia's health minister says the government will not negotiate the fundamentals of its Pharmaceutical Benefits Scheme with the US, despite new tariffs.

"We are not negotiating about those fundamentals. - Mark Butler"

Canberra, April 3

The Australian federal government will not make changes to its subsidization scheme for medications amid tariff pressure from the US administration, said Mark Butler, the health minister, on Friday.

Butler told Seven Network television that Australia will not negotiate with the United States on the "fundamentals" of the Pharmaceutical Benefits Scheme (PBS), under which the federal government subsidizes the cost of prescription medicines, Xinhua news agency reported.

"We keep sending this clearest of possible messages to the US because we know they get the big drug companies in their ear trying to unpick the PBS here in Australia and equivalent schemes in other countries around the world. We are not negotiating about those fundamentals," he said.

Butler was speaking after US President Donald Trump signed an executive order on Thursday imposing a 100 per cent tariff on imports of certain patented pharmaceuticals.

In an updated list of trade grievances with Australia released late in March, the US administration said that the PBS undervalues American innovation through unfair drug pricing practices.

Under the scheme, pharmaceutical manufacturers must negotiate sales directly with the Australian government rather than individual buyers to prevent commercial bidding wars.

According to data from the United Nations' Comtrade, Australian pharmaceutical exports to the United States were worth $1.3 billion in 2025.

Biotechnology giant CSL is Australia's largest pharmaceutical company, but Butler said on Friday the government is confident the Melbourne-based firm will be exempt from the new tariffs because of its large US manufacturing presence.

A spokesperson for trade minister Don Farrell told the Australian Broadcasting Corporation on Friday that the government was disappointed by the US tariffs on pharmaceuticals and would continue to push for the removal of "unjustified and unwarranted" tariffs.

- IANS

Share this article:

Reader Comments

R
Rohit P
$1.3 billion in exports is significant, but health of citizens is priceless. Australia's PBS scheme sounds similar to the intent behind our own price control mechanisms for essential drugs. The US approach seems very aggressive. Trade shouldn't come at the cost of public welfare.
A
Aman W
Interesting to see CSL might be exempt due to US manufacturing. Shows how global supply chains are intertwined. But the principle is important - governments must have the right to negotiate bulk prices for medicines. It's a matter of national health security.
S
Sarah B
While I support affordable medicine, I hope Australia's stance is carefully calibrated. A full-blown trade war helps no one, especially patients who rely on innovation. There has to be a middle path that rewards R&D while ensuring access.
V
Vikram M
"Undervalues American innovation" – this is the same argument used against India's patent laws. Every country has a right to decide how it values medicines for its population. The Australian model of direct government negotiation is actually very smart, prevents middlemen from inflating prices.
K
Karthik V
This is a bold move. Hope it inspires other nations. In India, we've seen the benefits of price controls on critical drugs. Health is a fundamental right, not a luxury commodity. The US tariffs seem like bullying tactics to force open markets on their terms only.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50